Abstract | BACKGROUND: METHODS: We investigated the influence of the molecule on postoperative bleeding after cardiac surgery, comparing 2 groups of patients undergoing emergency or urgent coronary artery bypass grafting: group A (n = 20) received tirofiban, and group B (n = 68) received conventional therapy with intravenous heparin up until the operation. A total of 88 patients underwent coronary artery bypass surgery within 2 hours of ceasing the hemodynamic study. Clinical outcome, chest tube outputs, bleeding complications, transfusion requirements, platelet and hemoglobin counts, and clinical complications were examined. RESULTS:
Bleeding differences were noted between the 2 groups at 8, 16, and 24 hours postoperatively. The incidence of blood, platelet, and fresh frozen plasma transfusions was higher in the control group. Postoperative thrombocytopenia was preserved in group A (199.5 +/- 70.4 vs 150.6 +/- 33.4 10(3)/mL, P <.01). No significant differences were noted between the 2 groups in the incidence of perioperative myocardial infarction, but significant differences were noted in enzyme levels, length of stay in the intensive care unit, and length of stay in the hospital. No deaths were observed. Hospital morbidity was increased in group B because of factors that were not apparently linked with tirofiban infusion. CONCLUSIONS:
|
Authors | F Bizzarri, S Scolletta, E Tucci, M Lucidi, G Davoli, T Toscano, E Neri, L Muzzi, G Frati |
Journal | The Journal of thoracic and cardiovascular surgery
(J Thorac Cardiovasc Surg)
Vol. 122
Issue 6
Pg. 1181-5
(Dec 2001)
ISSN: 0022-5223 [Print] United States |
PMID | 11726894
(Publication Type: Journal Article)
|
Chemical References |
- Platelet Aggregation Inhibitors
- Platelet Glycoprotein GPIIb-IIIa Complex
- Tyrosine
- Heparin
- Tirofiban
|
Topics |
- Blood Transfusion
(statistics & numerical data)
- Case-Control Studies
- Coronary Artery Bypass
- Emergencies
- Female
- Heparin
(therapeutic use)
- Humans
- Incidence
- Male
- Middle Aged
- Platelet Aggregation Inhibitors
(therapeutic use)
- Platelet Glycoprotein GPIIb-IIIa Complex
(antagonists & inhibitors)
- Postoperative Complications
(epidemiology)
- Postoperative Hemorrhage
(epidemiology)
- Time Factors
- Tirofiban
- Tyrosine
(analogs & derivatives, therapeutic use)
|